Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21458661 | 0.90 | MEN1 (0.40) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL6906272 | 0.89 | MEN1 (0.48) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL3346302 | 0.89 | MEN1 (0.48) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL1846778 | 0.89 | MEN1 (0.48) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL8455284 | 0.88 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL11577648 | 0.88 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL8854283 | 0.88 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL6901492 | 0.88 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL8499290 | 0.88 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL2909988 | 0.88 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326758-A1 | RICYCLIC HETEROARYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-12195470-B2 | 7-phenoxy-N-(3-azabicyclo[3.2.1]octan-8-yl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma- secretase modulators for the treatment of alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4424370-A2 | 7-PHENOXY-N-(3-AZABICYCLO[3.2.1LOCTAN-8-YL)-6,7-DIHYDRO-5H-PYRROLO[1,2-B][1,2,4]TRIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-09-04 | — | — | EP | disclosed |
| EP-3894411-B1 | 7-PHENOXY-N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)-6,7-DIHYDRO-5H-PYRROLO[1,2-B][1,2,4]TRIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2024-06-19 | — | — | EP | disclosed |
| CN-117946116-A | 6, 7-Dihydro-5H-pyrrolo [1,2-B ] [1,2,4] triazol-2-amine derivatives | 豪夫迈·罗氏有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-113179641-B | 6, 7-dihydro-5H-pyrrolo [1,2-B ] [1,2,4] triazol-2-amine derivatives | 豪夫迈·罗氏有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4093401-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | The Board of Regents of the University of Texas System (US) | 2022-11-30 | — | — | EP | disclosed |
| US-20220056036-A1 | 7-PHENOXY-N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)-6,7-DIHYDRO-5H-PYRROLO[1,2-B][1,2,4]TRIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3894411-A1 | 7-PHENOXY-N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)-6,7-DIHYDRO-5H-PYRROLO[1,2-B][1,2,4]TRIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-10-20 | — | — | EP | disclosed |
| WO-1996005195-A1 | NOVEL N-SUBSTITUTED NAPHTHOFUSED LACTAMS | NOVO NORDISK A/S (DK) | 1996-02-22 | — | — | WO | disclosed |
| US-4296042-A | Preparation of unsaturated aliphatic insect pheromones using cyclic phosphonium ylids | SYNTEX (U.S.A.) INC. (US) | 1981-10-20 | — | — | US | disclosed |
| US-4294708-A | FABRIC SOFTENERS | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1981-10-13 | — | — | US | disclosed |
| US-4283576-A | CHEMICAL INTERMEDIATES FOR 2-OXABICYCLO(2.2.2)OCTANE USED FOR PERFUMES AND FLAVORS | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1981-08-11 | — | — | US | disclosed |
| US-4273662-A | 2-Oxabicyclooctane derivatives, processes for preparing same and organoleptic uses thereof | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1981-06-16 | — | — | US | disclosed |
| US-4235729-A | 2-Oxabicyclooctane derivatives, processes for preparing same and organoleptic uses thereof | INTERNATIONAL FLAVORS & FRAGRANCES, INC. (US) | 1980-11-25 | — | — | US | disclosed |
| US-4229314-A | 2-Oxabicyclooctane derivatives, processes for preparing same and organoleptic uses thereof | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1980-10-21 | — | — | US | disclosed |
| US-4221721-A | 2-Oxabicyclooctane derivatives, processes for preparing same and organoleptic uses thereof | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1980-09-09 | — | — | US | disclosed |
| US-4208308-A | 2-Oxabicyclooctane derivatives in perfume compositions | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1980-06-17 | — | — | US | disclosed |
| US-4197328-A | 2-Oxabicyclooctane derivatives in augmenting or enhancing the aroma or taste of foodstuffs | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1980-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | EIF2AK2, SARS1, ACE | MEN1 4398/4885KMT2A 1142/4885KDM4C 738/4885 |
| US-20220056036-A1 | 7-PHENOXY-N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)-6,7-DIHYDRO-5H-PYRROLO[1,2-B][1,2,4]TRIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, PSEN1, APP | MEN1 206/4885KMT2A 2856/4885KDM4C 3753/4885 |
| US-12195470-B2 | 7-phenoxy-N-(3-azabicyclo[3.2.1]octan-8-yl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma- secretase modulators for the treatment of alzheimer's disease | BACE1, PSEN1, APP | MEN1 288/4885KMT2A 3048/4885KDM4C 3527/4885 |
| US-20250326758-A1 | RICYCLIC HETEROARYL DERIVATIVES | AR, CYP1B1, CYP1A1 | MEN1 295/4885KMT2A 605/4885KDM4C 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.